Friday’s Oval Office event was designed for maximum political effect. President Trump, flanked by HHS Secretary Robert F. Kennedy Jr. and CMS Administrator Mehmet Oz, announced that all 50 states, Washington, D.C., and Puerto Rico have applied to participate in his administration’s GENEROUS Medicaid pricing model, extending most-favored-nation drug pricing nationwide for participating Medicaid programs. Through MFN pricing, 26 of the world’s largest drugmakers representing roughly 90% of branded U.S. drugs have publicly pledged to support most-favored-nation pricing.
The companies who signed include nearly every name in a dividend investor’s healthcare sleeve: Pfizer, Eli Lilly, Novo Nordisk, Merck, Novartis, Sanofi, Johnson & Johnson, and AbbVie, whose deals were struck between late 2025 and earlier this year. Instinct says: sell. Reality is more layered.
What Medicaid Actually Represents
Before recalibrating a portfolio, income investors need to answer one question: how much of a given company’s revenue actually flows through Medicaid? The answer is less than the headline suggests.
Net spending on Medicaid prescription drugs is estimated to have grown from $31 billion in FY 2019 to $46 billion in FY 2024. That sounds large until you stack it against total U.S. drug spending, which runs well above $600 billion annually. Medicaid accounts for a fraction of the branded market for most large drugmakers, and that fraction varies sharply by company and by drug class.
The mechanism here is also important. Under the GENEROUS model, participating manufacturers will provide state Medicaid programs with rebates on expensive brand-name drugs to ensure the final price to Medicaid does not exceed the MFN price. Medicaid already collects mandatory rebates under existing law, meaning MFN adds an additional rebate layer on top of a channel that was already steeply discounted. For companies where Medicaid is a thin slice of total U.S. volume, the incremental hit to net revenue is measurable but not catastrophic.
The White House projects the 50-state participation unlocks about $64.3 billion in Medicaid drug savings over the next decade. Spread over ten years and across 26 manufacturers, that averages out to roughly $250 million per company per year before any mix or volume adjustments. For a company like AbbVie with 2026 revenue guidance of about $67.6 billion, or Lilly guiding to $85 to $87 billion in 2026 revenue, that is a rounding error, not a dividend threat.
Where Exposure Actually Concentrates
The calculus is not uniform. Drugs treating conditions that disproportionately affect low-income populations, including certain diabetes medications, antipsychotics, and respiratory therapies, carry higher Medicaid exposure than oncology or specialty biologics, where commercial and Medicare coverage dominate. The model covers a wide swath of drugs across major classes, and the breadth is where income investors should look carefully.
That breadth is where income investors should look carefully. A company like Merck, whose Keytruda revenue runs overwhelmingly through oncology channels and commercial insurance, faces a different Medicaid exposure profile than a company with large volumes in diabetes or cardiovascular medicine. Drug-level analysis matters more than company-level headlines.
The Durability Question
There is a second variable the dividend case must weigh: how permanent is this? Reporting earlier this year, STAT said SEC filings from some companies indicate parts of the deals are time-limited, with two companies specifying three-year terms. The White House’s broader savings projections depend on assumptions that extend well beyond those terms. Outside analysts and policy experts have also questioned the projections, in part because many deal details are not public.
That opacity cuts both ways. If the deal terms are softer than the headline suggests, the revenue impact on pharma is also softer. The voluntary framework’s existing-drug provisions are anchored in Medicaid, and the administration’s analysis separates that from a broader “prospective MFN” construct that it says would apply to future launches across all U.S. markets. Medicare is where the real volume sits for most branded blockbusters.
The Wealth-Building Takeaway
Dividend investors do not need to exit pharma over Friday’s announcement. They need to do the work the headlines skip. Pull each holding’s annual report, locate the U.S. government segment, and estimate what portion of U.S. net revenues actually originate from Medicaid. For most major names, that number is low enough that MFN rebates represent a manageable margin adjustment rather than a structural earnings impairment. The companies with concentrated exposure to Medicaid drug classes deserve closer scrutiny. For the rest, the more durable risk to the dividend case remains the patent cliff, not this pricing model.